Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.
<h4>Background</h4>The availability of H5N1 vaccines that can elicit a broad cross-protective immunity against different currently circulating clade 2 H5N1 viruses is a pre-requisite for the development of a successful pre-pandemic vaccination strategy. In this regard, it has recently be...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-02-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18301743/?tool=EBI |
| _version_ | 1818722473036742656 |
|---|---|
| author | Isabel Leroux-Roels Roger Bernhard Pascal Gérard Mamadou Dramé Emmanuel Hanon Geert Leroux-Roels |
| author_facet | Isabel Leroux-Roels Roger Bernhard Pascal Gérard Mamadou Dramé Emmanuel Hanon Geert Leroux-Roels |
| author_sort | Isabel Leroux-Roels |
| collection | DOAJ |
| description | <h4>Background</h4>The availability of H5N1 vaccines that can elicit a broad cross-protective immunity against different currently circulating clade 2 H5N1 viruses is a pre-requisite for the development of a successful pre-pandemic vaccination strategy. In this regard, it has recently been shown that adjuvantation of a recombinant clade 1 H5N1 inactivated split-virion vaccine with an oil-in-water emulsion-based adjuvant system also promoted cross-immunity against a recent clade 2 H5N1 isolate (A/Indonesia/5/2005, subclade 2.1). Here we further analyse the cross-protective potential of the vaccine against two other recent clade 2 isolates (A/turkey/Turkey/1/2005 and A/Anhui/1/2005 which are, as defined by WHO, representatives of subclades 2.2 and 2.3 respectively).<h4>Methods and findings</h4>Two doses of the recombinant A/Vietnam/1194/2004 (H5N1, clade 1) vaccine were administered 21 days apart to volunteers aged 18-60 years. We studied the cross-clade immunogenicity of the lowest antigen dose (3.8 microg haemagglutinin) given with (N = 20) or without adjuvant (N = 20). Immune responses were assessed at 21 days following the first and second vaccine doses and at 6 months following first vaccination. Vaccination with two doses of 3.8 microg of the adjuvanted vaccine induced four-fold neutralising seroconversion rates in 85% of subjects against A/turkey/Turkey/1/2005 (subclade 2.2) and 75% of subjects against A/Anhui/1/2005 (subclade 2.3) recombinant strains. There was no response induced against these strains in the non-adjuvanted group. At 6 months following vaccination, 70% and 60% of subjects retained neutralising antibodies against the recombinant subclade 2.2 and 2.3 strains, respectively and 40% of subjects retained antibodies against the recombinant subclade 2.1 A/Indonesia/5/2005 strain.<h4>Conclusions</h4>In addition to antigen dose-sparing, adjuvantation of inactivated split H5N1 vaccine promotes broad and persistent cross-clade immunity which is a pre-requisite for a pre-pandemic vaccine.<h4>Trial registration</h4>ClinicalTrials.gov NCT00309634. |
| first_indexed | 2024-12-17T20:55:11Z |
| format | Article |
| id | doaj.art-a7813e4354bb4b7dba661427c8f7607f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-17T20:55:11Z |
| publishDate | 2008-02-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a7813e4354bb4b7dba661427c8f7607f2022-12-21T21:32:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032008-02-0132e166510.1371/journal.pone.0001665Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.Isabel Leroux-RoelsRoger BernhardPascal GérardMamadou DraméEmmanuel HanonGeert Leroux-Roels<h4>Background</h4>The availability of H5N1 vaccines that can elicit a broad cross-protective immunity against different currently circulating clade 2 H5N1 viruses is a pre-requisite for the development of a successful pre-pandemic vaccination strategy. In this regard, it has recently been shown that adjuvantation of a recombinant clade 1 H5N1 inactivated split-virion vaccine with an oil-in-water emulsion-based adjuvant system also promoted cross-immunity against a recent clade 2 H5N1 isolate (A/Indonesia/5/2005, subclade 2.1). Here we further analyse the cross-protective potential of the vaccine against two other recent clade 2 isolates (A/turkey/Turkey/1/2005 and A/Anhui/1/2005 which are, as defined by WHO, representatives of subclades 2.2 and 2.3 respectively).<h4>Methods and findings</h4>Two doses of the recombinant A/Vietnam/1194/2004 (H5N1, clade 1) vaccine were administered 21 days apart to volunteers aged 18-60 years. We studied the cross-clade immunogenicity of the lowest antigen dose (3.8 microg haemagglutinin) given with (N = 20) or without adjuvant (N = 20). Immune responses were assessed at 21 days following the first and second vaccine doses and at 6 months following first vaccination. Vaccination with two doses of 3.8 microg of the adjuvanted vaccine induced four-fold neutralising seroconversion rates in 85% of subjects against A/turkey/Turkey/1/2005 (subclade 2.2) and 75% of subjects against A/Anhui/1/2005 (subclade 2.3) recombinant strains. There was no response induced against these strains in the non-adjuvanted group. At 6 months following vaccination, 70% and 60% of subjects retained neutralising antibodies against the recombinant subclade 2.2 and 2.3 strains, respectively and 40% of subjects retained antibodies against the recombinant subclade 2.1 A/Indonesia/5/2005 strain.<h4>Conclusions</h4>In addition to antigen dose-sparing, adjuvantation of inactivated split H5N1 vaccine promotes broad and persistent cross-clade immunity which is a pre-requisite for a pre-pandemic vaccine.<h4>Trial registration</h4>ClinicalTrials.gov NCT00309634.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18301743/?tool=EBI |
| spellingShingle | Isabel Leroux-Roels Roger Bernhard Pascal Gérard Mamadou Dramé Emmanuel Hanon Geert Leroux-Roels Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE |
| title | Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. |
| title_full | Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. |
| title_fullStr | Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. |
| title_full_unstemmed | Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. |
| title_short | Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. |
| title_sort | broad clade 2 cross reactive immunity induced by an adjuvanted clade 1 rh5n1 pandemic influenza vaccine |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18301743/?tool=EBI |
| work_keys_str_mv | AT isabellerouxroels broadclade2crossreactiveimmunityinducedbyanadjuvantedclade1rh5n1pandemicinfluenzavaccine AT rogerbernhard broadclade2crossreactiveimmunityinducedbyanadjuvantedclade1rh5n1pandemicinfluenzavaccine AT pascalgerard broadclade2crossreactiveimmunityinducedbyanadjuvantedclade1rh5n1pandemicinfluenzavaccine AT mamadoudrame broadclade2crossreactiveimmunityinducedbyanadjuvantedclade1rh5n1pandemicinfluenzavaccine AT emmanuelhanon broadclade2crossreactiveimmunityinducedbyanadjuvantedclade1rh5n1pandemicinfluenzavaccine AT geertlerouxroels broadclade2crossreactiveimmunityinducedbyanadjuvantedclade1rh5n1pandemicinfluenzavaccine |